Hope in the Midst of a Heart Failure Epidemic

Groundbreaking Biotechnology can Help Millions of Americans Suffering Cardiac Disease

Recent data gathered by leading heart research organizations clearly indicate that an epidemic of heart failure is gaining momentum in the United States.

According to the American Heart Association, almost 81 million American adults (one in three) suffer from one or more types of cardiovascular disease. Of those adults, more than 38 million are estimated to be 60 years or older.

Many instances of heart disease end badly; nearly 2,400 Americans die of cardiovascular disease every day - with an average of one death every 37 seconds.

Cardiovascular disease claims about as many lives annually as accidents, cancer, diabetes and chronic lower respiratory diseases combined.

Cardiovascular disease accounted for one of every 1.8 deaths in America in 2004. Cardiovascular disease is responsible for more deaths than any other single cause, or group of causes in America - and it's been that way for more than 100 years!

Types of cardiovascular disease include:

High blood pressure: 73 million Americans

Coronary heart disease: 16 million

MI - Myocardial infarction (heart attack)

Angina pectoris (chest pain)

Heart failure: approximately 6 million

More than 652,000 Americans died as a result of heart disease in 2005, as found by the National Center for Health Statistics (NCHS).

According to the NCHS, life expectancy would rise by almost seven years if all forms of major cardiovascular disease was eliminated. If all forms of cancer was eliminated, life expectancy would rise by only three years.

About 90 percent of coronary heart disease patients have been exposed to one or more of these risk factors:

High total blood cholesterol levels, or current medication with cholesterol-lowering drugs

Hypertension, or current meds with blood pressure-lowering drugs

Current cigarette use

Clinical report of diabetes

Women Health Heart Attack No Longer Male-Dominated Risk

In case you are reading this article as a woman, don't think your gender is getting off lightly in the heart failure epidemic. Consider the following facts:

Based on 2004 mortality statistics, cardiovascular disease led to about one death a minute among females.

More than 460,000 American women died from cardiovascular disease in 2004 - which was more female lives than claimed by cancer, Alzheimer's, stroke or chronic lower respiratory diseases that year.

The lifetime risk for cardiovascular disease is two in three for men, and one in two for women at age 40.

Because women have heart attacks at older ages than men, women are more likely to die from the heart attack within a few weeks.

Women experience different symptoms of heart attack than men, such as fatigue, indigestion, and shoulder and neck pain.

Health Psychology and Heart Disease

Aside from the physical health complications - and limitations in quality of life - that accompany cardiovascular disease, a person's psychological state can be greatly affected, adversely, from the condition. Many heart patients feel depressed because they aren't able to do the normal everyday activities that they used to do.

Adult Stem Cell Treatment Offers Hope for Victims of the Heart Failure Epidemic

A groundbreaking medical technology has been commercialized that uses adult stem cells for heart repair. TheraVitae - recognized by the World Economic Forum as a biotechnology pioneer - has been successfully providing its treatment, VesCell for Heart Disease, to patients from around the world.

An adult stem cell is one derived from the patient's own body (autologous). VesCell involves the patient providing a donation type of blood draw, the derivation, propagation, and differentiation of stem cells from the blood in five days, and the injection of the patient's own stem cells into his/her heart on the sixth day, a painless process conducted in comfort and style at a leading-edge Thai medical facility during a two-week stay.

TheraVitae is supported by hospital groups, physicians, and former patients who volunteer their time to speak to fellow sufferers of end-stage heart disease to help them understand the hope and promise afforded by VesCell. The company's clinical trial results and science are published in the Asian Cardiovascular & Thoracic Annals (PDF) (2008, Vol. 16, No. 2) and the British Journal of Haematology, respectively.

If you’d like to know more about VesCell adult stem cell therapy to address your heart disease or late-stage peripheral arterial disease, please contact Jerry@VesCell.com or dial 1-888-410-0902 or provide your contact information on the following form www.vescell.com/inquiry